dmd # 61473dmd.aspetjournals.org/content/dmd/early/2015/02/24/... · dmd # 61473 - 2 - running...
TRANSCRIPT
DMD # 61473
- 1 -
Systemic Exposure to and Disposition of Catechols
Derived from Salvia miltiorrhiza Roots (Danshen)
after Intravenous Dosing DanHong Injection in
Human Subjects, Rats, and Dogs
Meijuan Li, Fengqing Wang, Yühong Huang, Feifei Du, Chenchun
Zhong, Olajide E. Olaleye, Weiwei Jia, Yanfen Li, Fang Xu, Jiajia
Dong, Jian Li, Justin B. R. Lim, Buchang Zhao, Lifu Jia, Li Li, and
Chuan Li
Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai,
China (M.L., F.W., F.D., C.Z., O.E.O., W.J., F.X., J.D., J.L., J.B.R.L., L.L., C.L.);
University of Chinese Academy of Sciences, Shanghai, China (M.L., L.L., C.L.);
Second Affiliated Hospital, Tianjin University of Traditional Chinese Medicines, Tianjin,
China (Y.H. Y.L.); Buchang Pharmacy Group, Xi’an, Shaanxi Province, China (B.Z.,
L.J.); Institute of Chinese Materia Medica, China Academy of Chinese Medical
Sciences, Beijing, China (C.L.)
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on February 10, 2015 as DOI: 10.1124/dmd.114.061473
at ASPE
T Journals on A
ugust 1, 2020dm
d.aspetjournals.orgD
ownloaded from
DMD # 61473
- 2 -
Running Title: Systemic Exposure to Catechols from i.v. DanHong Injection
Address correspondence to: Drs. Chuan Li and Li Li, Laboratory for DMPK
Research of Herbal Medicines, Shanghai Institute of Materia Medica, Chinese
Academy of Sciences, 501 Haike Road, Zhangjiang Hi-Tech Park, Shanghai 201203,
China. E-mail: [email protected] (C. Li); [email protected] (L. Li)
Number of Text Pages: 26
Number of Tables: 2
Number of Figures: 6
Number of References: 40
Number of Words in Abstract Section: 250
Number of Words in Introduction Section: 738
Number of Words in Discussion Section: 1532
ABBREVIATIONS: ALDH, aldehyde dehydrogenase; AUC0-∞, area under plasma
concentration-time curve to infinity; COMT, catechol-O-methyltransferase; Cum.Ae-B,0-8h,
cumulative amount excreted into bile collected 0–24 h after dosing started; Cum.Ae-U,0-24h,
cumulative amount excreted into urine collected 0–24 h after dosing started; fe-B, fraction of
dose excreted into bile; fe-U, fraction of dose excreted into urine; PK, pharmacokinetic; SAH,
S-adenosylhomocysteine; SAM, S-adenosylmethionine; SULT, sulfotransferase; t1/2,
elimination half-life; TOF-MS, time-of-flight mass spectrometer; UGT, uridine
5’-diphospho-glucuronosyltransferase.
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on February 10, 2015 as DOI: 10.1124/dmd.114.061473
at ASPE
T Journals on A
ugust 1, 2020dm
d.aspetjournals.orgD
ownloaded from
DMD # 61473
- 3 -
ABSTRACT
DanHong injection is a Danshen (Salvia miltiorrhiza roots)-based injectable solution
for treatment of coronary artery disease and ischemic stroke. Danshen catechols are
believed to be responsible for the injection’s therapeutic effects. This study aimed to
characterize systemic exposure to and elimination of Danshen catechols in human
subjects, rats, and dogs receiving intravenous DanHong injection. A total of 28
catechols were detected, with content levels of 0.002–7.066 mM in the injection, and
the major compounds included tanshinol, protocatechuic aldehyde, salvianolic acid B,
rosmarinic acid, salvianolic acids A and D, and lithospermic acid with their daily doses
≥10 μmol/subject. After dosing, tanshinol, salvianolic acid D, and lithospermic acid
exhibited considerable exposure in human subjects and rats. However, only tanshinol
had considerable exposure in dogs. The considerable exposure to tanshinol was due
to its having the highest dose, while that to salvianolic acid D and lithospermic acid
was due to their relatively long elimination half-lives in the human subjects and rats.
Protocatechuic aldehyde and rosmarinic acid circulated in the bloodstream
predominantly as metabolites; salvianolic acids A and B exhibited low plasma levels
with their human plasma metabolites little or not detected. Tanshinol and salvianolic
acid D were eliminated mainly via renal excretion. Elimination of other catechols
involved hepatobiliary and/or renal excretion of their metabolites. Methylation was
found to be the primary metabolism for most Danshen catechols and showed
intercompound and interspecies differences in rate and degree in vitro. The
information gained here is relevant to pharmacological and toxicological research on
DanHong injection.
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on February 10, 2015 as DOI: 10.1124/dmd.114.061473
at ASPE
T Journals on A
ugust 1, 2020dm
d.aspetjournals.orgD
ownloaded from
DMD # 61473
- 4 -
Introduction
Traditionally, herbal medicines are orally administered. However, there are 134 types of
herbal injections that are approved by the China Food and Drug Administration (China FDA)
for clinical use. The herbal injections are prepared from a single herb or from a mixture of
several herbs and contain multiple bioactive compounds. The Chinese pharmaceutical
industry is required to manufacture herbal injection products in compliance with Good
Manufacturing Practice. Unlike orally administered herbal medicines, herbal injections are
injected directly into the bloodstream and potentially have immediate effects. Many approved
herbal injections are extensively used in Chinese hospitals for treating cardiovascular or
infectious diseases and for alleviating related symptoms; these herbal products appear to
exhibit comparable incidence of side effects with synthetic drug injections. However, active
compounds responsible for the therapeutic effects have remained poorly defined for most
herbal injections. This hampers investigating the mechanisms of action, optimizing the herbal
therapies, and assessing the safety and associated potential herb-drug interactions. Bioactive
herbal compounds that exhibit considerable levels of body exposure after administration are
most likely to account for the pharmacological effects of an herbal injection and form the
basis of therapeutic efficacy. Accordingly, pharmacokinetic (PK) studies should be designed
for herbal injections and implemented in human subjects and laboratory animals to reveal
body exposure to the herbal compounds after dosing. The body exposure to herbal compounds
depends on the doses of the compounds from the administered injection and their
pharmacokinetics and disposition after dosing. In the first step of PK studies of an herbal
injection, three questions should be answered: (i) what chemical compounds from the herbal
injection are injected into the bloodstream and how much are they dosed? (ii) Which herbal
compounds and herb-related metabolites exhibit considerable systemic exposure after dosing
and how long are their elimination half-lives? (iii) How are the herbal compounds that are
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on February 10, 2015 as DOI: 10.1124/dmd.114.061473
at ASPE
T Journals on A
ugust 1, 2020dm
d.aspetjournals.orgD
ownloaded from
DMD # 61473
- 5 -
considerably dosed from the injection principally eliminated? The first step of PK studies
provides information on which compounds derived from the herbal injection are worth further
investigation with respect to pharmacokinetics, pharmacology, and toxicology. The follow-up
PK studies should focus on these important herbal substances and should be carried out to
define their detailed pharmacokinetics and associated interindividual variations, to
characterize their principal routes of elimination, to quantify the contribution of enzymes and
transporters to their pharmacokinetics and disposition, and to assess associated potential
herb-drug and herb-herb interactions. Here, the aforementioned "first-step" PK studies were
designed for DanHong injection and implemented in human subjects, rats, and dogs.
DanHong injection is prepared from a 3:1 mixture of Salvia miltiorrhiza roots (Danshen
in Chinese) and Carthamus tinctorius flowers (Honghua). It is an injectable solution available
as a sterile, nonpyrogenic parenteral dosage form for intravenous injection. This herbal
injection is approved by the China FDA for the treatment of atherosclerotic coronary artery
disease and acute ischemic stroke. Several reports on meta-analyses of randomized trials
show that DanHong injection is effective in treating angina pectoris, congestive heart failure
and acute ischemic stroke (Peng et al., 2010; Peng et al., 2011; Yang et al., 2012). DanHong
injection contains multiple water-soluble polyphenols of Danshen-origin (Liu et al., 2013; Li
et al., 2013; Xie et al., 2014). The Danshen polyphenols contain one or more ortho-dihydroxy
benzene rings, known as catechols; have one or more carboxylic acid functional groups,
except for protocatechuic aldehyde. They are caffeic acid derivatives, occurring as monomers
(such as tanshinol and caffeic acid), dimers (such as rosmarinic acid and salvianolic acid D),
trimers (such as salvianolic acid A and lithospermic acid) and tetramers (such as salvianolic
acid B) (Jiang et al., 2005; Li et al., 2009). Cell- and isolated-tissue-based studies have shown
that Danshen catechols exhibited vasodilating, endothelial protective, cardioprotective,
antithrombotic, antioxidant, and antiinflammatory properties; tanshinol and other Danshen
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on February 10, 2015 as DOI: 10.1124/dmd.114.061473
at ASPE
T Journals on A
ugust 1, 2020dm
d.aspetjournals.orgD
ownloaded from
DMD # 61473
- 6 -
catechols also decreased blood pressure in rats and attenuated venular thrombosis, cardiac
hypertrophy, and methionine-induced hyperhomocysteinemia in rats (Jiang et al., 2005; Han
et al., 2008; Cao et al., 2009; Ho and Hong, 2011; Wang et al., 2013). Despite increasing
knowledge of the chemistry and pharmacology of DanHong injection, the systemic exposure
to and disposition of its bioactive compounds after dosing remain to be elucidated. This report
presents the Danshen-derived chemical profile of DanHong injection, the systemic exposure
to and elimination of Danshen catechols. It also presents comparative in vitro metabolic
stability of Danshen catechols towards various metabolic reactions and their in vitro
methylation profiles. The information gained here will be relevant to the optimization of
DanHong injection-based therapy.
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on February 10, 2015 as DOI: 10.1124/dmd.114.061473
at ASPE
T Journals on A
ugust 1, 2020dm
d.aspetjournals.orgD
ownloaded from
DMD # 61473
- 7 -
Materials and methods
DanHong injection. DanHong injection was manufactured by Heze Buchang
Pharmaceutical Co., Ltd. (Heze, Shandong Prov., China) with a China FDA ratification no. of
GuoYaoZhunZi-Z20026866. Each milliliter of DanHong injection was prepared from 0.75 g
of Salvia miltiorrhiza roots (Danshen) and 0.25 g of Carthamus tinctorius flowers (Honghua).
To prepare the herbal injection, Danshen and Honghua were mixed and extracted with water.
After filtration and concentration under reduced pressure, the concentrated extract was
precipitated with ethanol and centrifuged. The resulting supernatant was treated with active
carbon, evaporated under reduced pressure to remove the ethanol, adjusted to pH 6.5–7.5,
ultrafiltered, and sterilized. The finished product of DanHong injection was standardized to
contain not less than 0.35 mg/ml concentration of tanshinol and protocatechuic aldehyde
combined. Samples of six DanHong injection lots (lot numbers: 13011037, 13072016,
13082026, 13092035, 13102030, and 13122024) were obtained for analysis and all the
products were manufactured in 2013. DanHong injection that had the lot number 13011037
was used in the current human and animal studies.
Chemicals and reagents. Analytical reference standards of caffeic acid, lithospermic
acid, protocatechuic acid, protocatechuic aldehyde, rosmarinic acid, salvianolic acids A, B, C,
and D, tanshinol, chrysin, (−)-epicatechin, 7-hydroxyflavone, isovanillin, isovanillin acid and
vanillic acid were purchased from Tauto Biotech (Shanghai, China). The purity of the
preceding compounds was ≥98%. Pentobarbital was obtained from Shanghai Westang
Biotechnology (Shanghai, China).
S-adenosylmethionine (SAM), uridine 5′-diphospho-glucuronic acid (UDPGA),
3′-phosphoadenosine-5′-phosphosulfate (PAPS), tris-hydroxymethyl-aminomethane,
nicotinamide adenine dinucleotide (NAD+), taurocholic acid, formic acid, and methanol were
obtained from Sigma-Aldrich (St. Louis, MO, USA). Rat liver cytosol and microsomes and
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on February 10, 2015 as DOI: 10.1124/dmd.114.061473
at ASPE
T Journals on A
ugust 1, 2020dm
d.aspetjournals.orgD
ownloaded from
DMD # 61473
- 8 -
dog liver cytosol and microsomes were prepared in-house by differential centrifugation.
Human liver cytosol and microsomes were obtained from Corning Gentest (Woburn, MA,
USA). (−)-Epicatechin was used as the positive control to assess the
catechol-O-methyltransferase (COMT) activities of the human, rat, and dog liver cytosols
(Zhu et al., 2000; Li et al., 2012), and the in vitro t1/2 values were 0.46, 0.08, and 0.21 h,
respectively. 7-Hydroxyflavone was used as the positive control to assess the sulfotransferase
(SULT) activities of the human, rat, and dog liver cytosols (Li et al., 2012; Hu et al., 2013),
and the in vitro t1/2 values were 0.07, 0.29, and 0.10 h, respectively. Chrysin was used as the
positive control to assess the UDP-glycosyltransferase (UGT) activities of the human, rat, and
dog liver microsomes (Li et al., 2012; Hu et al., 2013), and the in vitro t1/2 values were 0.08,
0.05, 0.05 h, respectively. Isovanillin was used as the positive control to assess the aldehyde
dehydrogenase (ALDH) activities of the human, rat, and dog liver cytosols (Panoutssopoulos
et al., 2004), and the in vitro t1/2 values were 0.04, 0.05, and 0.05 h, respectively.
Human study. The protocol for human study was approved by the ethics committee of
clinical investigation at Second Affiliated Hospital of Tianjin University of Traditional
Chinese Medicine (Tianjin, China). The study was registered in Chinese Clinical Trials
Registry (www.chictr.org) with a registration number of ChiCTR-ONRC-13003571. Healthy
volunteers gave written informed consent to participate in the study. The human subjects were
considered to be in good health on the basis of medical history, physical examination, vital
signs measurement, electrocardiogram, and clinical laboratory tests. They were required to be
aged between 18 and 35 years, have a body mass index between 19 and 24 kg/m2, be a
nonsmoker, and not be allergic to products prepared from Danshen and/or Honghua. Synthetic
drugs and herbal products were prohibited starting from 2 weeks before the study began until
the end of the study period. In addition, alcoholic beverages were prohibited starting from 2
days before the study began until the end of the study period.
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on February 10, 2015 as DOI: 10.1124/dmd.114.061473
at ASPE
T Journals on A
ugust 1, 2020dm
d.aspetjournals.orgD
ownloaded from
DMD # 61473
- 9 -
A single-period, open-label human study was performed at a national clinical research
center of the Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine
(Tianjin, China). Six male subjects were asked to fast overnight before receiving a 120 min i.v.
infusion dose of DanHong injection (40 ml/person, a label daily dose) the next morning.
Before dosing, 40 ml of DanHong injection was diluted in 250 ml of 5% glucose injection
(GuoYaoZhunZi-H12020021; China Otsuka Pharmaceutical Co., Ltd., Tianjin, China). Serial
blood samples (~1 ml, collected in heparinized tubes) were taken from an antecubital vein
catheter at 0, 0.25, 0.5, 1, 2, 2.17, 2.5, 3.5, 5, 11, and 24 h after the i.v. infusion was started.
The blood samples were heparinized and centrifuged to obtain plasma fractions. 0.1 ml
aliquots of the resulting plasma samples of the same time point were pooled and stored at
−70°C until analysis. Urine samples were collected predose and at 0–2, 2–6, 6–10, and 10–24
h postdose and weighed. 1 ml aliquots of the urine samples within the same time interval were
pooled prior to storage at −70°C without use of any preservative. Serum alanine
aminotransferase, aspartate aminotransferase, total protein, albumin/globulin ratio, total
bilirubin, and direct bilirubin were monitored as liver function markers for the human subjects
before and 24 h after dosing of DanHong injection; serum creatinine and blood urea nitrogen
were also assessed to monitor human renal function.
Laboratory animals. All animal studies were conducted in compliance with the
Guidance for Ethical Treatment of Laboratory Animals (the Ministry of Science and
Technology of China, 2006). The experimental protocols were approved by the Institutional
Animal Care and Use Committee at Shanghai Institute of Materia Medica (Shanghai, China).
Male Sprague-Dawley rats (230–270 g) were obtained from Sino-British SIPPR/BK
Laboratory Animal (Shanghai, China). Rats were maintained in a unidirectional airflow room
at 20–24°C and relative humidity between 30% and 70% with a 12 h light/dark cycle. Rats
were given filtered tap water and commercial rat chow ad libitum and allowed to acclimate to
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on February 10, 2015 as DOI: 10.1124/dmd.114.061473
at ASPE
T Journals on A
ugust 1, 2020dm
d.aspetjournals.orgD
ownloaded from
DMD # 61473
- 10 -
the facilities and environment for three days before use. Rats received in-house
femoral-artery-cannulation for blood sampling or bile-duct-cannulation for bile sampling
(Chen et al., 2013; Cheng et al., 2013). After surgery, rats were housed individually and
allowed to regain their preoperative body weights before further use. During the bile
collection period, a sodium taurocholate solution (pH 7.4) was infused into the duodena of
bile-duct-cannulated rats at 1.5 ml/h. After use, rats were euthanized with CO2.
Male beagle dogs (7.8–9.0 kg) were obtained from the Teaching and Research Farm of
Agricultural College, Shanghai Jiao Tong University (Shanghai, China) and were individually
housed in stainless steel cages (1.7 × 1.0 × 0.9 m), which could be used to collect urine
samples. The dogs were maintained at a controlled temperature of 20–24°C, relative humidity
between 40% and 70%, and a 12-h cycle of light and dark. They were given commercial diets,
except for an overnight fasting period before dosing, and filtered tap water ad libitum. The
dogs were acclimated to the facilities for 2 weeks before use.
Rat studies. Conscious and freely moving rats received a single i.v. bolus dose of
DanHong injection at 4 ml/kg. The dose of the herbal injection for the rats was derived from
the clinical daily dose (40 ml/person) according to dose normalization by body surface area
(Reagan-Shaw et al., 2008). Serial blood samples (~150 µl; immediately before and 5, 15, and
30 min and 1, 2, 4, 6, 8, 11, and 24 h after dosing) were collected from three
femoral-artery-cannulated rats into heparinized tubes. The blood samples were centrifuged to
obtain the plasma fractions and the resulting plasma samples (0.05 ml) of the same time point
were pooled. Bile samples were collected from three bile-duct-cannulated rats before and 0–1,
1–2, 2–4, 4–6, and 6–8 h after dosing. Three rats that did not undergo any surgical treatment
were housed individually in metabolic cages. Urine samples were collected before and 0–4,
4–8, and 8–24 h after dosing; samples (0.5 ml) of the same collection period from different
rats were pooled and stored at −70°C until analysis.
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on February 10, 2015 as DOI: 10.1124/dmd.114.061473
at ASPE
T Journals on A
ugust 1, 2020dm
d.aspetjournals.orgD
ownloaded from
DMD # 61473
- 11 -
Dog study. Dogs received a single i.v. bolus dose of DanHong injection at 1.2 ml/kg.
The dog dose was derived from the clinical daily dose of the herbal injection (40 ml/person)
according to dose normalization by body surface area (Reagan-Shaw et al., 2008). Serial
blood samples (~500 µl; immediately before and 5, 15, 30 min and 1, 2, 4, 6, 8, 11, and 24 h
after dosing) were collected from three dogs into heparinized tubes. The blood samples were
centrifuged to obtain the plasma fractions and the resulting plasma samples (0.1 ml) of the
same time point were pooled. Urine samples were also collected from the dogs before and 0–4,
4–8, and 8–24 h after dosing. The urine samples (0.5 ml) from the same collection period
were pooled. The samples from dogs were stored at −70°C until analysis.
In vitro metabolism studies. Comparative metabolic stability of several Danshen
catechols toward COMT, SULT, UGT, and ALDH (ALDH for protocatechuic aldehyde only)
was assessed with human, rat, and dog liver cytosols and microsomes. The test Danshen
catechol compounds were tanshinol, protocatechuic aldehyde, protocatechuic acid, salvianolic
acid B, rosmarinic acid, salvianolic acids A and D, and lithospermic acid. Before use, the
COMT, SULT, and ALDH activities of the liver cytosols were assessed with the reference
compounds (−)-epicatechin, 7-hydroxyflavone, and isovanillin, respectively; the UGT
activities of liver microsomes was assessed with chrysin. The liver cytosol was fortified with
an appropriate cofactor (SAM for methylation, PAPS for sulfation, and NAD+ for oxidation)
and the liver microsomes were fortified with UDPGA for glucuronidation. The reaction was
initiated by adding the test compound (10 μM) at 37ºC and terminated at 0, 15 (for rat
enzyme-mediated reactions only), 30 (for dog enzyme-mediated reactions only), and 60 min
(for human enzyme-mediated reactions only) by adding a double volume of ice-cold methanol.
The time of incubation for tanshinol was double that for the other Danshen catechol
compounds. Negative control reactions were carried out by incubating mixtures that excluded
the cytosol or the microsomes. The quenched incubation was centrifuged at 1369g for 10 min
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on February 10, 2015 as DOI: 10.1124/dmd.114.061473
at ASPE
T Journals on A
ugust 1, 2020dm
d.aspetjournals.orgD
ownloaded from
DMD # 61473
- 12 -
and 5 μl of the supernatant were analyzed by liquid chromatography/mass spectrometry.
Metabolic stability was calculated as percentage of unchanged compound remaining after
incubation. When determining the metabolic stability of protocatechuic aldehyde toward
COMT and SULT present in human liver cytosol, isovanillin (100 μM) was used to inhibit the
catalytic activity of the coexisting ALDH.
In vitro methylation was further examined individually for the preceding Danshen
catechol compounds by incubating with human, rat, and dog liver cytosols fortified with
COMT. The incubation broth contained 0.5 mg protein/ml liver cytosol, 50 mM Tris-HCl
buffer (pH 7.4), 1 mM dithiothreitol, 2 mM MgCl2, and 1 mM SAM and was preincubated for
3 min at 37ºC before initiation of reaction by adding the test compound (10 μM). After
incubation for 0, 5, 15, 30, 60, 90, and 120 min at 37ºC, the reactions were terminated by
adding a double volume of ice-cold methanol. After centrifugation, the supernatant (5 μl) was
analyzed to profile unchanged substrate and methylated metabolites. In the determination of
in vitro t1/2, the concentrations of the test Danshen catechol in the incubation broth over time
were calculated as percentage of compound remaining, using the initial concentration (the
incubation time, 0 min) as 100%. The slope of the linear regression from log percentage
remaining versus incubation time relationship, i.e., −k, was used in the calculation of in vitro
t1/2, according to the following equation:
In vitro t1/2 = 0.693/k (1)
Analysis of Danshen catechol compounds and the metabolites. A Waters Synapt G2
high definition time-of-flight mass spectrometer (TOF-MS; Manchester, UK) was interfaced
via a Zspray/LockSpray ESI source with a Waters Acquity UPLC separation module (Milford,
MA, USA). The mass spectrometer was operated in resolution mode giving a resolving power
of around 20000. The ESI source worked in the negative ion mode under the following
conditions: capillary voltage at −2.5 kV, source temperature of 120°C, desolvation gas at 800
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on February 10, 2015 as DOI: 10.1124/dmd.114.061473
at ASPE
T Journals on A
ugust 1, 2020dm
d.aspetjournals.orgD
ownloaded from
DMD # 61473
- 13 -
L/h and 400°C, sampling cone at 25 V, and extraction cone at 4.0 V. The mass spectrometer
was externally calibrated over a range of m/z 50–1000 using a 5 mM sodium formate solution
at 20 μL/min and mass shifts during acquisition were corrected using leucine enkephalin (m/z
554.2615) as a lockmass. MSE data acquisition (in centroid mode, m/z 50–1000) was achieved
using a trap collision energy of 4 V, a trap collision energy ramp of 15–30 V simultaneously
and a scan time of 0.3 s. Chromatographic separation of Danshen catechol compounds in
DanHong injection was achieved on a Waters Acquity UPLC HSS T3 1.8-μm column (100 ×
2.1 mm i.d.; Dublin, Ireland; kept at 45°C) using a mobile phase that consisted of solvent A
(methanol/water, 1:99, v/v, containing 25 mM formic acid) and solvent B (methanol/water,
99:1, v/v, containing 25 mM formic acid). The mobile phase was delivered at 0.3 ml/min. A
gradient program was used as follows: 0–2 min, at 2% solvent B; 2–32 min, from 2% to 98%
solvent B; 32–37 min, at 98% solvent B; and 37–42 min, at 2% solvent B. For quantitative
analysis of Danshen compounds, a modified gradient elution program with a mobile phase
flow rate of 0.3 ml/min was used as follows: 0–10 min, from 2% to 70% solvent B; 10–12
min, from 70% to 98% solvent B; and 12–15 min, at 2% solvent B. Sample preparation for
human, rat, and dog samples was performed using methanol as precipitant with a volumetric
precipitant-to-sample ratio of 3:1. After precipitation and centrifugation, the supernatants
were reduced to dryness by centrifugal evaporation under reduced pressure. The residues were
reconstituted in 50% methanol for LC/TOF-MSE-based analysis.
Profiling of Danshen compounds in the samples of DanHong injection was conducted.
The detected compounds were identified by comparing with the reference standards, with
respect to accurate molecular mass, fragmentation, and chromatographic retention time. When
the reference standard was not available, the compound identification was achieved by
comparing the compound’s accurate molecular mass, fragmentation, and elution order with
the reported data of Danshen compounds. To support the metabolite profiling, an Accelrys
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on February 10, 2015 as DOI: 10.1124/dmd.114.061473
at ASPE
T Journals on A
ugust 1, 2020dm
d.aspetjournals.orgD
ownloaded from
DMD # 61473
- 14 -
metabolite database (version 2012.1; Accelrys, Inc., San Diego, CA, USA) was used to get
prior knowledge of likely metabolic pathways of Danshen compounds. Metabolite profiling
was conducted with the human, rat, and dog samples according to the molecular mass gains or
losses predicted for the possible metabolites compared with those of the parent compounds
and according to the generation of fragment ions from the precursor deprotonated molecules
by collision-induced dissociation. The MS fragmentation data were also used to assign the
metabolite structures. Methylated metabolites were characterized by the comparative
fragmentation profiles of metabolite and parent compound. Glucuronides and sulfates were
characterized by neutral losses of 176 and 80 Da, respectively. Quantification of Danshen
catechols and the metabolites in the biological samples was performed using the available
reference standards for calibration or using the calibration curve of an analog (also called
“brother compound”) that bore close structural similarity to the analyte (Li et al., 2012).
Using the reference standards, matrix-matched calibration curves (13.7–10000 nM) were
constructed using weighted linear regression of the peak area against the corresponding
nominal analyte concentration (nM), which showed good linearity (r2 >0.99). Assay
validation was carried out according to the US FDA guidance on bioanalytical validation
(2013) to prove that the bioanalytical assays were reliable for the intended applications.
PK data analysis. The area under plasma concentration-time curve up to the last
measured time point (AUC0-t) was calculated by the trapezoidal rule. The AUC0-∞ was
generated by extrapolating the AUC0-t to infinity using the elimination rate constant (k) and
the last measured concentration. The elimination half-life (t1/2) was calculated using the
relationship 0.693/k. The cumulative amounts excreted into urine (Cum.Ae-U) and bile
(Cum.Ae-B) were calculated by numeric integration of the amount excreted per collection
interval. The fractions of dose excreted into urine (fe-U) and bile (fe-B) were established by
Cum.Ae-U/dose and Cum.Ae-B/dose, respectively.
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on February 10, 2015 as DOI: 10.1124/dmd.114.061473
at ASPE
T Journals on A
ugust 1, 2020dm
d.aspetjournals.orgD
ownloaded from
DMD # 61473
- 15 -
Results
Danshen catechols present in DanHong injection. Three literature references by Liu et
al. (2007), Wang et al. (2007), and Li et al. (2009) give the most comprehensive information
about chemical constituents present in Danshen. Among the Danshen constituents,
hydrophilic catechols and lipophilic diterpene quinones are pharmacologically relevant.
However, only the Danshen catechols, but not the diterpene quinones, were detected in
DanHong injection. This is probably because of water extraction of the herb involved in
manufacturing the injection. As shown in Table 1 and Fig. 1, a total of 28 Danshen catechol
compounds were detected in six lots of DanHong injection with tanshinol (6) present in the
highest content level (6.139–7.066 mM). Other major Danshen compounds present were
protocatechuic aldehyde (1; 1.474–1.840 mM), salvianolic acid B (26; 1.014–1.245 mM),
rosmarinic acid (10; 0.684–0.795 mM), salvianolic acids A (16; 0.563–0.886 mM) and D (13;
0.467–0.704 mM), lithospermic acid (22; 0.235–0.322 mM), salvianolic acid B isomer (25;
0.159–0.227 mM), and salvianolic acid E (27; 0.136–0.154 mM). These were major Danshen
catechols, which have LogP values of −0.28–2.69 (calculated using Pallas software, Pallas
3.7.1.1; CompuDrug International, Sedona, AZ, USA). The remaining Danshen compounds,
which were also detected in the herbal injection samples, were salvianolic acid B isomer (24),
lithospermic acid isomers (18, 19, and 20), caffeic acid (3), protocatechuic acid (2),
salviaflaside (17), salvianolic acids H/I (21), F (7), J (23), G (8), and C (15), salvianic acid C
(11) and salvianic acid C isomer (12), isosalvianolic acid C (14), prolithospermic acid (9),
isoferulic acid (5), ferulic acid (4), and 4-methoxyl salvianolic acid B (28). These minor
Danshen compounds exhibited content levels of 0.002–0.076 mM with LogP values of
0.17–3.02. Lot-to-lot variability of DanHong injection was also investigated with the major
constituents (≥0.136 mM). The herbal injection showed consistency in the content levels of 6,
1, 26, 10, and 27 from lot to lot. This was indicated by relative standard deviations (RSD) of
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on February 10, 2015 as DOI: 10.1124/dmd.114.061473
at ASPE
T Journals on A
ugust 1, 2020dm
d.aspetjournals.orgD
ownloaded from
DMD # 61473
- 16 -
4.3–9.4%. Such RSD values for 16, 13, 22, and 25 were greater, i.e., 12.0%–16.3%.
(Insert Table 1 and Figure 1 here)
DanHong injection (lot number, 13011037) was used in the current study; the content
levels of tanshinol (6), protocatechuic aldehyde (1), salvianolic acid B (26), rosmarinic acid
(10), salvianolic acid A (16), salvianolic acid D (13), and lithospermic acid (22) were 7.066,
1.833, 1.013, 0.769, 0.886, 0.704, and 0.247 mM, respectively. Clinical daily dose levels of
the Danshen catechols from the herbal injection could be divided into three classes: >100,
10–100, and <10 μmol/subject (Fig. 1C). The dose level of 6 was 282.8 μmol/subject, which
was 52.7% of the total dose of Danshen catechols detected in the injection (Fig. 1D); 6 was a
Danshen catechol of class I. The dose levels of 1, 26, 10, 16, 13, and 22 were 10.0–73.2
μmol/subject, the sum of which accounted for 40.7% of the total dose of Danshen catechols
detected in the injection; these compounds were of class II. The remaining Danshen catechols
were of class III with dose levels of 0.1–7.2 μmol/subject, the sum of which accounted for
only 6.6% of the total dose of Danshen catechols detected in the injection.
Unchanged Danshen catechols detected in plasma and urine samples of human
subjects receiving an i.v. infusion dose of DanHong injection. In the current study, pooled
human plasma samples and pooled human urine samples were used for the detection of
unchanged Danshen catechols and related metabolites. This was because the detection of
Danshen compounds depended on factors, such as assay sensitivity and interindividual
variations in the elimination mediated by drug metabolizing enzymes and/or drug transporters.
The samples were pooled to minimize the possibility of failed detection of important herbal
compounds and their metabolites due to the potential influence of interindividual variation in
their elimination. A total of 11 Danshen catechols were detected in human plasma samples
during and after i.v. infusion of DanHong injection; they were not detected in the control
plasma samples before dosing. Tanshinol (6) was detected in considerable amount in the
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on February 10, 2015 as DOI: 10.1124/dmd.114.061473
at ASPE
T Journals on A
ugust 1, 2020dm
d.aspetjournals.orgD
ownloaded from
DMD # 61473
- 17 -
plasma samples after dosing started. Although salvianolic acid D (13) and lithospermic acid
(22) were Danshen catechols of class II with content levels being only 10.0% and 3.5% of that
of 6, respectively, their levels of systemic exposure were comparable with that of 6 (Fig. 2A).
The other Danshen catechols detected in plasma, including salvianolic acids B (26) and A (16),
rosmarinic acid (10), and protocatechuic acid (2), were at low AUC0-∞ levels (Fig. 2A). The
observed high levels of systemic exposure to 13 and 22 were probably associated with their
longer t1/2 values (2.5 and 5.7 h, respectively) compared with those of 6 (0.6 h) and the other
Danshen catechols (around 0.2 h). Only trace amounts of protocatechuic aldehyde (1),
lithospermic acid isomers (19 and 20) and salvianolic acid C (15) were detected in plasma.
Plasma concentrations of 6, 13, and 22 over time during and after an i.v. infusion dose of
DanHong injection in human subjects are shown in Supplemental Fig. 1.
A considerable amount of tanshinol (6) from i.v. dosed DanHong injection was recovered
in human urine with a fe-U of 63.3%. Although the fe-U value of salvianolic acid D (13; 62.7%)
was almost the same as that of 6, its Cum.Ae-U,0-24h was only 8.6% of that of 6 (Fig. 2B). The
difference in urinary Cum.Ae-U,0-24h between the two catechols was associated mainly with the
difference in their content levels in DanHong injection; the content level of 13 was 10.0% of
that of 6 (Fig. 1B). Only 3.8% of lithospermic acid (22) from i.v. dosed DanHong injection
was excreted unchanged into the urine and its Cum.Ae-U,0-24h was quite low (Fig. 2B). Other
plasma Danshen catechols [including salvianolic acid B (26) and rosmarinic acid (10)] were
also detected in urine with fe-U values of 0.2% and 18.2%, respectively; salvianolic acid A (16)
was not detected in urine.
Metabolites of Danshen catechols detected in plasma and urine samples of human
subjects receiving the i.v. infusion dose of DanHong injection. Metabolites detected in the
human samples after dosing were those of the major Danshen catechols. As shown in Fig. 3A,
the major Danshen catechols could be divided into three categories according to their
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on February 10, 2015 as DOI: 10.1124/dmd.114.061473
at ASPE
T Journals on A
ugust 1, 2020dm
d.aspetjournals.orgD
ownloaded from
DMD # 61473
- 18 -
circulating pattern; (i) tanshinol (6), salvianolic acid D (13), and lithospermic acid (22):
circulating mainly as parent compound with minor or major metabolites, (ii) protocatechuic
aldehyde (1) and rosmarinic acid (10): circulating in the bloodstream predominantly as
metabolites with a minor parent compound, and (iii) salvianolic acids B (26) and A (16): only
minor parent compound circulating in the bloodstream with metabolites very little or not
detected. The major metabolites of Danshen catechols were the methylated metabolites and
their further sulfated and glucuronized products. Sulfates and glucuronides of Danshen
catechols were also detected in plasma after dosing. Table 2 shows LC/TOF-MSE-based
detection of the individual metabolites of Danshen catechols in human plasma and/or urine
during and after the i.v. infusion dose of DanHong injection, as well as the metabolite ID
notation system. Fig. 3A and B exhibit plasma AUC0-∞ and Cum.Ae-U,0-24h of metabolites in
comparison with the respective data of their parent Danshen catechols. Fig. 4 depicts major
metabolic pathways proposed for Danshen catechols from i.v. dosed DanHong injection in
humans. The major metabolite of 6 was M6M; this metabolite was eliminated mainly via renal
excretion. M13M was a detected metabolite of 13 and its Cum.Ae-U,0-24h was 6.6% of the
amount of 13 dosed from DanHong injection. The major metabolite of 22 was M222M, which
was poorly eliminated via renal excretion. Protocatechuic aldehyde has been reported to
convert into protocatechuic acid by ALDH (Panoutsopoulos and Beedham, 2005; Xu et al.,
2007). Consistent with this, the total Cum.Ae-U,0-24h of protocatechuic acid (2) and its
metabolites (including M2M, M2M-G-1, M2M-G-2, M2S-1, and M2S-2) after dosing exceeded the
amount of 2 dosed from DanHong injection by 28 fold. This suggested that 1 was eliminated
mainly by oxidation into 2, which was further methylated, glucuronized, and sulfated before
renal excretion of 2 and the metabolites. The major metabolites of 10 included M10M-2,
M102M, M102M-S-1, M102M-S-2, M102M-G-1, and M102M-G-2; these metabolites were eliminated
considerably via renal excretion with a total Cum.Ae-U,0-24h being 44.3% of the amount of 10
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on February 10, 2015 as DOI: 10.1124/dmd.114.061473
at ASPE
T Journals on A
ugust 1, 2020dm
d.aspetjournals.orgD
ownloaded from
DMD # 61473
- 19 -
dosed from DanHong injection. Like in the plasma samples, no metabolite of 26 was detected
in the associated urine samples. Unchanged 16 from DanHong injection was not detected in
urine; only four minor urinary metabolites (M16M-G-1, M16M-G-2, M16M-G-3, M16G-2) were
detected for 16. The total Cum.Ae-U,0-24h of these metabolites was only 1.0% of the amount of
16 dosed from DanHong injection. These data suggested that 26, 16, and their metabolites in
humans were not eliminated mainly via renal excretion.
Danshen catechols and metabolites detected in plasma, urine, and bile samples of
rats and dogs after dosing DanHong injection. For rats and dogs, samples of the same kind
and from the same collection time points/intervals were pooled to minimize the possibility of
failed detection of important herbal compounds and their metabolites; this sample pooling
treatment was similar to that for human subjects. Like for human subjects, tanshinol (6),
salvianolic acid D (13), and lithospermic acid (22) were the most abundant Danshen
compounds detected in rat plasma samples after dosing DanHong injection (Fig. 2C). In rats,
the t1/2 values of 13 and 22 (1.8 and 1.9 h, respectively) were longer than that of 6 (0.3 h).
Protocatechuic aldehyde (1), Rosmarinic acid (10), salvianolic acids B (26) and A (16) were
also detected in the rat plasma samples, but at low AUC0-∞ levels (Fig. 2C). Their t1/2 values
ranged from 0.2 h to 0.8 h.
In rats, both tanshinol (6) and salvianolic acid D (13) were eliminated mainly via renal
excretion (fe-U, 54.3% and 53.6%, respectively), rather than hepatobiliary excretion (fe-B, 0.5%
and 1.0%, respectively), after dosing DanHong injection (Fig. 2D and E). Their major
metabolites M6M, M6S, and M13M exhibited lower levels of systemic exposure than their
respective parent compounds (Fig. 3C). These metabolites were also eliminated mainly via
renal excretion (Fig. 3D and E); the total Cum.Ae-U,0-24h of M6M and M6S and Cum.Ae-U,0-24h of
M13M were 29.1% and 20.0% of the amounts of 6 and 13, respectively, dosed from DanHong
injection. Lithospermic acid (22) was not eliminated mainly via renal excretion (fe-U, 2.7%) or
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on February 10, 2015 as DOI: 10.1124/dmd.114.061473
at ASPE
T Journals on A
ugust 1, 2020dm
d.aspetjournals.orgD
ownloaded from
DMD # 61473
- 20 -
hepatobiliary excretion (fe-B, 1.2%) (Fig. 2D and E). Its metabolites M222M and M22M were
substantially detected in rat plasma and bile after dosing (Fig. 3C and E). The hepatobiliary
excretion of these metabolites were significantly greater than their renal excretion (Fig. 3D
and E); their total Cum.Ae-B,0-8h and total Cum.Ae-U,0-24h were 76.9% and 4.7%, respectively, of
the amount of 22 dosed from DanHong injection. Protocatechuic aldehyde (1) was eliminated
mainly via oxidation into protocatechuic acid (2) followed by further methylation and
sulfation; sulfation also considerably occurred in rats for 1 (Fig. 3D and E). The urinary
recovery of 2 and the follow-up metabolites (M2M-S, M2S-1, and M2S-2) in rats exceeded the
amount of 2 dosed from DanHong injection by 109 fold, which was markedly greater than
that observed in human subjects (28 fold). This was, at least in part, because the rat diet
contained a considerable amount of p-hydroxybenzoic acid ethylester. It has been reported
that p-hydroxybenzoic acid esters can be hydrolyzed and hydroxylated into protocatechuic
acid (Wang et al. 2013). Rosmarinic acid (10) was eliminated more extensively via renal
excretion (fe-U, 25.2%) than hepatobiliary excretion (fe-B, 0.12%) (Fig. 2D and E). Unlike in
the human subjects, 10 exhibited a higher level of systemic exposure than its metabolites
(M102M, M102M-S-1, M102M-S-2, M102M-G-1, and M102M-G-2) in rats (Fig. 3C). These
metabolites were eliminated via both renal and hepatobiliary excretion (Fig. 3D and E); their
total Cum.Ae-U,0-24h and total Cum.Ae-B,0-8h were 29.0% and 49.4%, respectively, of the amount
of 10 dosed from DanHong injection. Salvianolic acid B (26) was eliminated more
extensively via hepatobiliary excretion (fe-B, 8.1%) than renal excretion (fe-U, 1.0%) (Fig. 2D
and E). Its major metabolites included M26M, M262M-1, M262M-2, M263M-1, and M263M-2;
neither sulfate nor glucuronide of 26 was detected. These metabolites were eliminated mainly
via hepatobiliary excretion, rather than renal excretion (Fig. 3D and E); their total
Cum.Ae-B,0-8h and total Cum.Ae-U,0-24h were 90.1% and 0.6%, respectively, of the amount of 26
dosed from DanHong injection. Salvianolic acid A (16) was eliminated more extensively via
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on February 10, 2015 as DOI: 10.1124/dmd.114.061473
at ASPE
T Journals on A
ugust 1, 2020dm
d.aspetjournals.orgD
ownloaded from
DMD # 61473
- 21 -
hepatobiliary excretion (fe-B, 9.3%) than renal excretion (fe-U, 0.5%) (Fig. 2D and E). Unlike in
the human subjects, the metabolites M16M-G-1, M162M-G-1, M162M-G-3, and M16G-1 appeared to
have higher levels of systemic exposure than unchanged 16 in rats (Fig. 3C). In addition to
these plasma metabolites, M16M-G-2, M16M-G-3, and M162M-G-2 were considerably detected in
bile. Like the parent compound, the detected metabolites were eliminated mainly via
hepatobiliary excretion (Fig. 3D and E); their total Cum.Ae-B,0-8h was 71.8% of the amount of
16 dosed from DanHong injection. Supplemental Table 1 shows LC/TOF-MSE-based
detection of the individual metabolites of Danshen catechols in rat plasma, urine, and/or bile
after dosing DanHong injection.
In dogs, only plasma tanshinol (6) was considerably detected after dosing DanHong
injection (Fig. 2F). Unlike in the human subjects and in the rats, plasma salvianolic acid D (13)
and lithospermic acid (22) were detected at low levels in dogs after dosing. Their t1/2 values
were 0.2 h and 0.5 h, which were shorter than that of 6 (1.0 h). Salvianolic acids B (26) and A
(16) and rosmarinic acid (10) were also detected in plasma but at low levels of systemic
exposure with t1/2 of 0.2–0.3 h (Fig. 2F). Only trace amounts of protocatechuic aldehyde (1)
was detected in canine plasma. The fe-U values of 6, 13, and 22 were 34.5%, 43.6%, and 5.8%,
respectively (Fig. 2G). M6M and M6S appeared to be substantially formed in dogs (Fig. 3G);
their Cum.Ae-U,0-24h were 14.1% and 48.4%, respectively, of the amount of 6 dosed from
DanHong injection. However, their plasma AUC0-∞ values were lower than that of the parent
compound 6 (Fig. 3F). The elimination of 1 mainly involved oxidation into protocatechuic
acid (2) followed by further methylation and sulfation (Fig. 3F and G). The urinary recovery
of 2 and the follow-up metabolites (M2M and M2M-S) in dogs exceeded the amount of 2 dosed
from DanHong injection by 12 fold. Multiple metabolites of 10 were detected in plasma but at
lower levels than the parent compound (Fig. 3F); they included M10M-1, M10M-2, M102M,
M102M-S-1, and M102M-S-2. The Cum.Ae-U,0-24h of unchanged 10 and the total Cum.Ae-U,0-24h of
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on February 10, 2015 as DOI: 10.1124/dmd.114.061473
at ASPE
T Journals on A
ugust 1, 2020dm
d.aspetjournals.orgD
ownloaded from
DMD # 61473
- 22 -
its metabolites were 5.1% and 21.9%, respectively, of the amount of 10 dosed from DanHong
injection. The metabolites of 13, 22, 16, and 26 were detected at low levels in canine plasma
and urine after dosing (Fig. 3F and G). Supplemental Table 2 shows LC/TOF-MSE-based
detection of the individual metabolites of Danshen catechols in canine plasma and/or urine
after dosing DanHong injection.
Comparative metabolism of Danshen catechols mediated by hepatic COMT, SULT,
UGT, and ALDH. In vitro methylation, sulfation, and glucuronidation of the Danshen
catechols (tanshinol, protocatechuic aldehyde, protocatechuic acid, salvianolic acid B,
rosmarinic acid, salvianolic acid A, salvianolic acid D, and lithospermic acid) were compared,
with respect to percentage of compound remaining after incubation with human, rat, and dog
hepatic enzymes for a certain length of time. Among the human hepatic enzyme-mediated
metabolic reactions, the rates of methylation of the test compounds were greater than those of
associated sulfation and glucuronidation, except for protocatechuic aldehyde and salvianolic
acid A (Fig. 5A). Sulfation and glucuronidation of salvianolic acid D, lithospermic acid, and
salvianolic acid B appeared to be negligible, because the sulfates and glucuronides were not
detected after incubation. Glucuronidation and oxidation of protocatechuic aldehyde were
significantly faster than its methylation. Glucuronidation of salvianolic acid A was
significantly faster than its methylation. Similar scenarios were observed for the rat and dog
hepatic enzyme-mediated metabolic reactions, except for rat COMT-mediated methylation of
protocatechuic aldehyde comparably as fast as the ALDH-mediated oxidation (Fig. 5B and C).
The in vitro catalytic activities of the rat and dog enzymes appeared to be higher than those of
the human enzymes. Accordingly, the incubation times used for the rat and dog enzymes to
mediate metabolism reactions were shorter than those of the human enzymes, i.e., 15 min (30
min for tanshinol only), 30 min (60 min for tanshinol only), 60 min (120 min for tanshinol
only), respectively.
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on February 10, 2015 as DOI: 10.1124/dmd.114.061473
at ASPE
T Journals on A
ugust 1, 2020dm
d.aspetjournals.orgD
ownloaded from
DMD # 61473
- 23 -
The rates of human hepatic COMT-mediated methylation of the different test Danshen
catechol compounds were considerably different (Fig. 6A). This is indicated by in vitro t1/2
values, which were ranked as follows: salvianolic acid D (0.31 h) ≈ lithospermic acid (0.41 h)
≈ protocatechuic acid (0.44 h) < salvianolic acid B (0.73 h) < rosmarinic acid (1.23 h) <
salvianolic acid A (3.25 h) ≈ protocatechuic aldehyde (3.71 h) ≈ tanshinol (3.73 h). The results
of in vitro metabolite profiling of the incubations indicated that the methylation degree was
catechol-moiety-number-dependent and incubation-time-dependent. Tanshinol, protocatechuic
aldehyde, and protocatechuic acid contain only one catechol moiety; only mono-methylated
metabolites (M6M, M1M, and M2M) were detected for these Danshen catechol compounds.
Rosmarinic acid and lithospermic acid contain two unsubstituted catechol moieties. Both
monomethylated (M10M-1, M10M-2, and M22M) and dimethylated metabolites (M102M and
M222M) of rosmarinic acid and lithospermic acid were found to be predominant and the
formation of dimethylated metabolites was significantly delayed as compared with that of
monomethylated metabolites. Salvianolic acid D contains one unsubstituted catechol moiety
and one substituted catechol moiety; it was converted predominantly into a monomethylated
metabolite (M13M-1). Its dimethylated metabolite was detected at very low levels. Salvianolic
acid B contains three unsubstituted catechol moieties and salvianolic acid A contains two
unsubstituted catechol moieties and one substituted catechol moiety. Human COMT-mediated
methylation of these catechol compounds resulted in the formation of monomethylated
(M16M-1, M16M-2, and M26M) and dimethylated metabolites (M162M-1, M162M-2, M262M-1,
and M262M-2), but only trace amounts of the trimethylated metabolites were detected. The
rates of methylation mediated by the rat and the dog COMTs were significantly faster than
those by the human enzyme (Fig. 6B and C). Due to this faster methylation by the rat COMT,
trimethylated metabolites (M163M-1, M163M-2, M263M-1, and M263M-2) were significantly
detected for salvianolic acids A and B (Fig. 6B). For the dog COMT, these trimethylated
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on February 10, 2015 as DOI: 10.1124/dmd.114.061473
at ASPE
T Journals on A
ugust 1, 2020dm
d.aspetjournals.orgD
ownloaded from
DMD # 61473
- 24 -
metabolites were also considerably detected only after 120-min incubation (Fig. 6C). For the
rat hepatic COMT-mediated methylation, the in vitro t1/2 values were ranked as follows:
lithospermic acid (0.04 h) = salvianolic acid B (0.04 h) = rosmarinic acid (0.04 h) ≈
salvianolic acid D (0.05 h) < salvianolic acid A (0.09 h) ≈ protocatechuic acid (0.12 h) <
protocatechuic aldehyde (0.24 h) < tanshinol (0.94 h). For the dog hepatic COMT-mediated
methylation, the in vitro t1/2 values were ranked as follows: lithospermic acid (0.10 h) ≈
salvianolic acid D (0.13 h) < protocatechuic acid (0.25 h) ≈ rosmarinic acid (0.28 h) ≈
salvianolic acid B (0.30 h) ≈ salvianolic acid A (0.39 h) < protocatechuic aldehyde (1.36 h) <
tanshinol (1.94 h).
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on February 10, 2015 as DOI: 10.1124/dmd.114.061473
at ASPE
T Journals on A
ugust 1, 2020dm
d.aspetjournals.orgD
ownloaded from
DMD # 61473
25
Discussion
Danshen catechols are pharmacologically important for DanHong injection; they have
been reported to have multiple antianginal properties. Because systemic exposure to
compounds after dosing an herbal injection depends on their dose levels and elimination
kinetics, defining the correlations between exposure and influencing factors are important in
PK research on the injection. The analysis of DanHong injection revealed a total of 28
Danshen catechols present. Because of their different content levels, these Danshen catechols
could be divided into three classes according to their daily dose levels from the i.v. injection.
Tanshinol (6; 282.8 μmol/subject) was the only Danshen catechol of class I (>100
μmol/subject). Protocatechuic aldehyde (1), salvianolic acids B (26) and A (16), rosmarinic
acid (10), salvianolic acid D (13), and lithospermic acid (22) had dose levels of 10.0–73.2
μmol/subject; they were Danshen catechols of class II (10–100 μmol/subject). The other 21
minor Danshen catechols (0.1–7.2 μmol/subject) were of class III (<10 μmol/subject). In the
human subjects receiving DanHong injection, Danshen catechols of classes I and II were all
detected in plasma. However, only few Danshen catechols of class III, including lithospermic
acid isomers (19 and 20; 5.2 and 3.9 μmol/subject, respectively) and protocatechuic acid (2;
1.9 μmol/subject), were detected in human plasma after dosing. Similar
compound-dose-dependent detection of plasma Danshen catechols took place in rats and
dogs.
Among the detected Danshen catechols, tanshinol (6), salvianolic acid D (13), and
lithospermic acid (22) exhibited the most significant systemic exposure in the human subjects
receiving DanHong injection, suggesting that these herbal compounds are worth special
consideration in pharmacological research on DanHong injection. Unlike 6 (the only Danshen
catechol of class I), 13 and 22 were Danshen catechols of class II and exhibited content levels
in the dosed injection lower than the other catechols of the same class. The considerable
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on February 10, 2015 as DOI: 10.1124/dmd.114.061473
at ASPE
T Journals on A
ugust 1, 2020dm
d.aspetjournals.orgD
ownloaded from
DMD # 61473
26
systemic exposure to 13 and 22 appeared to be correlated with their elimination half-lives (t1/2,
2.5 and 5.7 h, respectively) significantly longer than those of 6 and the other Danshen
catechols of class II (0.2–0.6 h). Rats and dogs are laboratory animals extensively used in
cardiovascular pharmacological research. Rats receiving DanHong injection exhibited an
exposure profile of unchanged Danshen catechols similar to the human subjects; 6, 13, and 22
exhibited levels of systemic exposure higher than the other Danshen catechols. In the rats, the
t1/2 values of 13 and 22 (around 2 h) were longer than those of 6 and the other Danshen
catechols of class II (<1 h). Unlike the human subjects and the rats, dogs exhibited
considerable systemic exposure to 6 only after dosing DanHong injection. In the dogs, 13 and
22 exhibited short t1/2 (<0.5 h). The observed PK interspecies difference should be considered
in pharmacological research of DanHong injection. In PK studies of other herbal medicines,
significant differences in elimination half-life have also been found to cause considerably
different systemic exposure to herbal compounds; long elimination half-life may considerably
counterbalance influence of poor oral bioavailability on systemic exposure to an herbal
compound (Liu et al., 2009; Chen et al., 2013; Jiang et al., 2015). With rapidly increasing
application of analytical techniques, such as liquid chromatography/mass spectrometry, in
research on herbal medicines, content levels of compounds in herbal formulations and their
elimination half-lives have become more and more available in literature; such data of herbal
compounds could be used together as potential PK marker to predict their systemic exposure
after dosing herbal injections.
Besides the systemic exposure to unchanged Danshen catechols, their elimination was
also investigated in the current study. After dosing DanHong injection, tanshinol (6),
salvianolic acid D (13), and lithospermic acid (22) circulated mainly as parent compound with
minor or major metabolites. Elimination of 6 and 13 mainly involved renal excretion of the
parent compounds, while 22 was eliminated mainly via hepatic uptake and methylation
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on February 10, 2015 as DOI: 10.1124/dmd.114.061473
at ASPE
T Journals on A
ugust 1, 2020dm
d.aspetjournals.orgD
ownloaded from
DMD # 61473
27
followed by hepatobiliary excretion of the metabolites. Unlike these three catechols,
protocatechuic aldehyde (1) circulated in the blood stream predominantly as metabolites,
rather than the parent compound, and was first transformed into protocatechuic acid (2),
which was then eliminated by conversion into sulfates and methylated glucuronides followed
by renal excretion. Rosmarinic acid (10) also circulated in the blood stream predominantly as
metabolites, rather than the parent compound. This catechol was eliminated mainly via
metabolism and only about 20% of dosed 10 was eliminated via renal excretion of the parent
compound. The metabolism of 10 involved formation of dimethylated products and their
sulfates and glucuronides; these metabolites were eliminated comparably via renal excretion
and hepatobiliary excretion. Salvianolic acids A (16) and B (26) were detected at low plasma
levels and their plasma metabolites exhibited little or no detection in the human subjects.
These two Danshen catechols appeared to be eliminated mainly via hepatobiliary excretion of
glucuronized and methylated metabolites of 16 and methylated metabolites of 26. Zhang et al.
(2004) reported several hepatobiliary metabolites of salvianolic acid B in rats, including
3-monomethyl-, 3,3"-dimethyl-, 3,3'"-dimethyl-, and 3,3",3'"-trimethyl-salvianolic acid B.
The Danshen catechols have poor membrane permeability, except for protocatechuic
aldehyde (Lu et al., 2008). During elimination, these compounds tend to necessitate
transporter-mediated basolateral uptake from blood as the first step in hepatobiliary and/or
renal tubular elimination. Hepatic OATP1B3 and renal OAT1 were found to mediate cellular
uptake of Danshen catechols (the details to be published elsewhere). Because of their catechol
moieties, most Danshen catechols underwent COMT-mediated methylation as the primary
metabolic pathway in humans, rats, and dogs. Significant intercompound and interspecies
differences in rate and degree of methylation were observed for Danshen catechols. Hepatic
methylation of tanshinol by human COMT was significantly slower than those of salvianolic
acid D and lithospermic acid, demonstrating their in vitro t1/2 3.73, 0.31, and 0.41 h,
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on February 10, 2015 as DOI: 10.1124/dmd.114.061473
at ASPE
T Journals on A
ugust 1, 2020dm
d.aspetjournals.orgD
ownloaded from
DMD # 61473
28
respectively. However, the elimination t1/2 of tanshinol (6; 0.6 h) after dosing DanHong
injection in human subjects was significantly shorter than those of salvianolic acid D (13; 2.5
h) and lithospermic acid (22; 5.7 h). This is probably because the transporter-mediated hepatic
and/or renal tubular uptake from blood, rather than the methylation, was the rate-limiting step
in the elimination of these Danshen catechols. Although methylation of drugs often hampers
their pharmacological activities (Goldstein et al., 2003), the antianginal properties of the
major methylated metabolites of Danshen catechols are unknown.
Methylation of xenobiotics with catechol moieties involves COMT-catalyzed transfer of
methyl groups from SAM to the catechol hydroxyl groups in the presence of Mg2+ (Zhu et al.,
2002). This produces S-adenosylhomocysteine (SAH), which can be further converted to
homocysteine by SAH hydrolase in the liver and kidneys (to less extent). An abnormally high
blood concentration of homocysteine is recognized as a risk factor for vascular diseases and
neurodegenerative conditions (McCully et al., 2007; Vogle et al., 2009; Smith et al., 2010).
This has raised concerns regarding untoward effects of hepatic methylation of xenobiotics on
the blood concentration of homocysteine. A typical example is hyperhomocysteinemia, which
is caused by chronic levodopa treatment of patients with Parkinson’s disease (Kuhn, et al.,
1998; Müller et al., 1999; Miller et al., 2003). The Danshen catechols from i.v. DanHong
injection undergo COMT-mediated methylation in the body. Further investigation of the
relationship between methylation of Danshen catechols and hyperhomocysteinemia risk may
facilitate hazard identification for this herbal injection. This may also improve understanding
of the endothelial protection properties of Danshen catechols (Chan et al., 2004; Yang et al.,
2010; Cao et al., 2009; Zhang et al., 2013).
In summary, Danshen catechols present in DanHong injection could be divided,
according to their daily dose levels, into three classes (>100, 10–100, and <10 μmol/subject).
Tanshinol (6) was the only Danshen catechol of class I; protocatechuic aldehyde (1),
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on February 10, 2015 as DOI: 10.1124/dmd.114.061473
at ASPE
T Journals on A
ugust 1, 2020dm
d.aspetjournals.orgD
ownloaded from
DMD # 61473
29
salvianolic acids B (26) and A (16), rosmarinic acid (10), salvianolic acid D (13), and
lithospermic acid (22) were of class II; the other 21 minor Danshen catechols were of class III.
Unchanged Danshen catechols of classes I and II were all detected in plasma after i.v. dosing
DanHong injection; only three catechols of class III were detected in plasma, but at very low
levels. Only 6, 13, and 22 exhibited considerable systemic exposure in human subjects
receiving the injection. These three catechols exhibited considerable systemic exposure also
in rats after dosing, but only 6 had considerable exposure in dogs. The considerable exposure
to 6 was due to its highest daily dose, while that to 13 and 22 was due to their relatively long
elimination half-lives. The catechols 1 and 10 circulated in the blood stream predominantly as
metabolites, rather than the parent compound; 16 and 26 were detected at low plasma levels
with their plasma metabolites little or not detected in the human subjects. Both 6 and 13 were
eliminated mainly via renal excretion of the parent compounds; 22 was eliminated mainly via
hepatobiliary excretion of its methylated metabolites. The other Danshen catechols were
eliminated mainly via hepatobiliary and/or renal excretion of their metabolites.
COMT-mediated methylation was found to be the primary metabolism for most Danshen
catechols and showed intercompound and interspecies differences in rate and degree. Because
the only known mechanism of homocysteine production involves SAM-dependent
methylation, further studies are warranted to fully characterize the methylation of Danshen
catechols and to address safety concern associated with possible alteration of blood
concentrations of homocysteine related to using DanHong injection.
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on February 10, 2015 as DOI: 10.1124/dmd.114.061473
at ASPE
T Journals on A
ugust 1, 2020dm
d.aspetjournals.orgD
ownloaded from
DMD # 61473
30
Authorship Contributions
Participated in research design: C. Li, L. Li, Huang.
Conducted experiments: L. Li, M. Li, Wang, Huang, Y. Li, Zhong, Du, W. Jia, Dong, J. Li, Xu.
Contributed new reagents: Zhao, L. Jia.
Performed data analysis: C. Li, M. Li, L. Li.
Wrote or contributed to the writing of the manuscript: C. Li, M. Li, L. Li, Olaleye, Lim.
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on February 10, 2015 as DOI: 10.1124/dmd.114.061473
at ASPE
T Journals on A
ugust 1, 2020dm
d.aspetjournals.orgD
ownloaded from
DMD # 61473
- 31 -
References
Cao Y, Chai J-G, Chen Y-C, Zhao J, Zhou J, Shao J-P, Ma C, Liu X-D, and Liu X-Q (2009)
Beneficial effects of danshensu, an active component of Salvia miltiorrhiza, on
homocysteine metabolism via the trans-sulphuration pathway in rats. Br J Pharmacol
157:482–490.
Chan K, Chui S-H, Wong D-Y, Ha W-Y, Chan C-L, and Wong R-N (2004) Protective effects
of Danshensu from the aqueous extract of Salvia miltiorrhiza (Danshen) against
homocysteine-induced endothelial dysfunction. Life Sci 75:3157–3171.
Chen F, Li L, Xu F, Sun Y, Du F-F, Ma X-T, Zhong C-C, Li X-X, Wang F-Q, Zhang N-T, and
Li C (2013) Systemic and cerebral exposure to and pharmacokinetics of flavonols and
terpene lactones after dosing standardized Ginkgo biloba leaf extracts to rats via different
routes of administration. Br J Pharmacol 170:440–457.
Cheng C, Liu X-W, Du F-F, Li M-J, Xu F, Wang F-Q, Liu Y, Li C, and Sun Y (2013) Sensitive
assay for measurement of volatile borneol, isoborneol, and the metabolite camphor in rat
pharmacokinetic study of Borneolum (Bingpian) and Borneolum syntheticum (synthetic
Bingpian). Acta Pharmacol Sin 34:1337–1348.
Goldstein DS, Eisenhofer G, Kopin IJ (2003) Sources and significance of plasma levels of
catechols and their metabolites in human. J Pharmacol Exp Ther 305: 800-811.
Han J-Y, Fan J-Y, Horie Y, Miura S, Cui D-H, Ishii H, Hibi T, Tsuneki H, Kimura I. (2008)
Ameliorating effects of compounds derived from Salvia miltiorrhiza root extract on
microcirculatory disturbance and target organ injury by ischemia and reperfusion.
Pharmacol Ther 117:280-295.
Ho J-H and Hong C-Y (2011) Salvianolic acids: small compounds with multiple mechanisms
for cardiovascular protection. J Biomed Sci 18:30-34.
Hu Z-Y, Yang J-L, Cheng C, Huang Y-H, Du F-F, Wang F-Q, Niu W, Xu F, Jiang R-R, Gao
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on February 10, 2015 as DOI: 10.1124/dmd.114.061473
at ASPE
T Journals on A
ugust 1, 2020dm
d.aspetjournals.orgD
ownloaded from
DMD # 61473
- 32 -
X-M, and Li C (2013) Combinatorial metabolism notably affects human systemic exposure
to ginsenosides from orally administered extract of Panax notoginseng roots (Sanqi). Drug
Metab Dispos 41:1457–1469.
Jiang R-R, Dong J-J, Li X-X, Du F-F, Jia W-W, Xu F, Wang F-Q, Yang J-L, Niu W, and Li C
(2015) Molecular mechanisms governing different pharmacokinetics of ginsenosides and
potential for ginsenoside-perpetrated herb-drug interactions on OATP1B3. Br J Pharmacol
172:1059–1073.
Jiang R-W, Lau K-M, Hon P-M, Mak T-C, Woo K-S, and Fung K-P (2005). Chemistry and
biologcal activities of caffeic acid derivatives from Salvia miltiorrhiza. Curr Med Chem
12:237–246.
Kuhn W, Roebroek R, Blom H, van Oppenraaij D, and Muller T (1998)
Hyperhomocysteinaemia in Parkinson's disease. J Neurol 245:811–812.
Li L, Zhao Y-S, Du F-F, Yang J-L, Xu F, Niu W, Ren Y-H, and Li C (2012) Intestinal
absorption and presystemic elimination of various chemical constituents present in GBE50
extract, a standardized extract of Ginkgo biloba leaves. Curr Drug Metab 13:494–509.
Li M-H, Li Q-Q, Zhang C-H, Zhang N, Cui Z-H, Huang L-Q, and Xiao P-G (2013) An
ethnopharmacological investigation of medicinal Salvia plants (Lamiaceae) in China. Acta
Pharm Sin B 3: 273-280.
Li Y-G, Song L, Liu M, Hu Z-B, Wang Z-T (2009) Advancement in analysis of Salviae
miltiorrhizae Radix et Rhizoma (Danshen). J Chromatogr A 1216:1941–1953.
Liu A-H, Guo H, Ye M, Lin Y-H, Sun J-H, Xu M, Guo D-A (2007) Detection, characterization
and identification of phenolic acids in Danshen using high-performance liquid
chromatography with diode array detection and electrospray ionization mass spectrometry.
J Chromatogr A 1161:170–182.
Liu H-F, Yang J-L, Du F-F, Gao X-M, Ma X-T, Huang Y-H, Xu F, Niu W, Wang F-Q, Mao Y,
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on February 10, 2015 as DOI: 10.1124/dmd.114.061473
at ASPE
T Journals on A
ugust 1, 2020dm
d.aspetjournals.orgD
ownloaded from
DMD # 61473
- 33 -
Sun Y, Lu T, Liu C-X, Zhang B-L, and Li C (2009) Absorption and disposition of
ginsenosides after oral administration of Panax notoginseng extract to rats. Drug Metab
Dispos 37:2290–2298.
Liu H-T, Wang Y-F, Olaleye O, Zhu Y, Gao X-M, Kang L-Y, and Zhao T (2013)
Characterization of in vivo antioxidant constituents and dual-standard quality assessment of
Danhong injection. Biomed Chromatogr 27:655–663.
Lu T, Yang J-L, Gao X-M, Chen P, Du F-F, Sun Y, Wang F-Q, Xu F, Shang H-C, Huang Y-H,
Wang Y, Wan R-Z, Liu C-X, Zhang B-L, and Li C (2008) Plasma and urinary tanshinol
from Salvia miltiorrhiza (Danshen) can be used as pharmacokinetic markers for cardiotonic
pills, a cardiovascular herbal medicine. Drug Metab Dispos 36:1578–1586.
McCully KS (2007) Homocysteine, vitamins, and vascular disease prevention. Am J Clin Nutr
86:1563S–1568S.
Miller JW, Selhub J, Nadeau MR, Thomas CA, Feldman RG, and Wolf PA (2003) Effect of
L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status. Neurology
60:1125–1129.
Müller T, Werne B, Fowler B, and Kuhn W (1999) Nigral endothelial dysfunction,
homocysteine, and Parkinson's disease. Lancet 354:126–127.
Panoutsopoulos GI and Beedham C (2005) Enzymatic oxidation of vanillin, isovanillin and
protocatechuic aldehyde with freshly prepared Guinea pig liver slices. Cell Physiol
Biochem 15:89–98.
Panoutsopoulos GI, Kouretas D, and Beedham C (2004) Contribution of aldehyde oxidase,
xanthine oxidase, and aldehyde dehydrogenase on the oxidation of aromatic aldehyde.
Chem. Res.Toxicol. 17:1368–1376.
Peng L-H, Sheng C-L, and Yu Z (2010) DanHong injection for ischemic stroke: a systemic
review. Chin Licenced Pharmacist. 7:3-11.
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on February 10, 2015 as DOI: 10.1124/dmd.114.061473
at ASPE
T Journals on A
ugust 1, 2020dm
d.aspetjournals.orgD
ownloaded from
DMD # 61473
- 34 -
Peng L-H, Yu Z, and Sheng C-L (2011) DanHong injection for angina pectoris: a systemic
review. Chin J Evid-Based Med. 11:57-63.
Reagan-Shaw S, Nihal M, and Ahmad N (2008) Dose translation from animal to human
studies revisited. FASEB J 22:659–661.
Smith AD, Smith SM, de Jager CA, Whitbread P, Johnston C, Agacinski G, Oulhaj A, Bradley
KM, Jacoby R, and Refsum H (2010) Homocysteine-lowering by B vitamins slows the rate
of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial.
PLoS One 5:e12244.
Tian D-D, Jia W-W, Liu X-W, Wang D-D, Liu J-H, Dong J-J, Li L, Du F-F, Xu F, Wang F-Q,
Sun Y, Huang Y-X, Li M-J, Hu L-H, Zhu Y, Li C, and Yang J-L (2015) Methlation and its
role in disposition of tanshinol, a cardiovascular carboxylic catechol from Salvia
miltiorrhiza roots (Danshen). Acta Pharmacol Sin
Vogel T, Dali-Youcef N, Kaltenbach G, and Andres E (2009) Homocysteine, vitamin B12,
folate and cognitive functions: a systematic and critical review of the literature. Int J Clin
Pract 63:1061–1067.
Wang J, Xiong X-J, and Feng B (2013) Cardiovascular effects of salvianolic acid B. Evid
Based Complement Alternat Med 2013:247948.
Wang L, Wu Y-H, Zhang W, and Kannan K (2013) Characteristic profiles of urinary
p-hydroxybenzoic acid and its esters (parabens) in children and adults from the United
States and China. Environ Sci Technol 47:2069–2076.
Wang L, Zhang Q, Li X-C, Lu Y-L, Xue Z-M, Xuan L-J, and Wang Y-P (2008)
Pharmacokinetics and metabolism of lithospermic acid by LC/MS/MS in rats. Int J Pharm
350: 240-246.
Wang X-H, Morris-Natschke SL, and Lee KH (2007) New developments in the chemistry and
biology of the bioactive constituents of Tanshen. Med Res Rev 27:133–148.
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on February 10, 2015 as DOI: 10.1124/dmd.114.061473
at ASPE
T Journals on A
ugust 1, 2020dm
d.aspetjournals.orgD
ownloaded from
DMD # 61473
- 35 -
Xie Y-Y, Xiao X, Luo J-M, Fu C, Wang Q-W, Wang Y-M, Liang Q-L, and Luo G-A (2014)
Integrating qualitative and quantitative characterization of traditional Chinese medicine
injection by high-performance liquid chromatography with diode array detection and
tandem mass spectrometry. J Sep Sci 37:1438–1447.
Xu M, Zhang Z-C, Fu G, Sun S-F, Sun J-H, Yang M, Liu A-H, Han J, and Guo D-A (2007)
Liquid chromatography-tandem mass spectrometry analysis of protocatechuic aldehyde and
its phase I and II metabolites in rat. J Chromatogr B Analyt Technol Biomed Life Sci
856:100–107.
Yang R-X, Huang S-Y, Yan F-F, Lu X-T, Xing Y-F, Liu Y, Liu Y-F, and Zhao Y-X (2010)
Danshensu protects vascular endothelia in a rat model of hyperhomocysteinemia. Acta
Pharmacol Sin 31:1395–1400.
Yang Y and Zeng L-X (2012) Meta-analysis on the efficacy and safety of DanHong injection
in the treatment of cerebral infarction. Chin J Gen Pract. 11:372-375.
Zhang W-T, He H, Wang H-D, Wang S-J, Li X, Liu Y, Jiang H-Y, Jiang H, Yan Y-D, Wang
Y-X, and Liu X-Q (2013) Activation of transsulfuration pathway by salvianolic acid a
treatment: a homocysteine-lowering approach with beneficial effects on redox homeostasis
in high-fat diet-induced hyperlipidemic rats. Nutr Metab 10:68.
Zhang Y, Akao T, Nakamura N, Hattori M, Yang X-W, Duan C-L, and Liu J-X (2004)
Magnesium lithospermate B is excreted rapidly into rat bile mostly as methylated
metabolites, which are potent antioxidants. Drug Metab Dispos 32:752–757.
Zhu B-T, Patel UK, Cai M-X, and Conney AH (2000) O-Methylation of tea polyphenols
catalyzed by human placental cytosolic catechol-O-methyltransferase. Drug Metab Dispos
28:1024–1030.
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on February 10, 2015 as DOI: 10.1124/dmd.114.061473
at ASPE
T Journals on A
ugust 1, 2020dm
d.aspetjournals.orgD
ownloaded from
DMD # 61473
- 36 -
Footnotes
This work was supported by the National Science Fund of China for Distinguished Young Scholars
[Grant 30925044]; the National Science and Technology Major Project of China “Key New Drug Creation
and Manufacturing Program” [Grants 2009ZX09304-002 and 2013ZX09201020001003]; and the National
Basic Research Program of China [Grant 2012CB518403].
This work was present in part as a poster presentation: Li L et al (2014) In vivo chemical profiles and
metabolic profiles of phenolic acids after intravenous administration of DanHong injection in different
species. 5th Asian Pacific Regional Meeting of ISSX; 2014 May 9-12; Tianjin, China. Justin B. R. Lim was a
visiting student from Ernest Mario School of Pharmacy, Rutgers, the State University of New Jersey, USA.
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on February 10, 2015 as DOI: 10.1124/dmd.114.061473
at ASPE
T Journals on A
ugust 1, 2020dm
d.aspetjournals.orgD
ownloaded from
DMD # 61473
- 37 -
Legends for Figures
FIG. 1. LC/TOF-MSE-based detection and measurement of Danshen catechols present in
DanHong injection. A, chromatogram of DanHong injection; B, average content levels of
Danshen catechols in different lots of DanHong injection in mM; C, clinical daily doses of
Danshen catechols from i.v. DanHong injection (lot number, 13011037) in μmol/subject; D,
percentages of individual catechols in total content level of Danshen catechols in DanHong
injection. Danshen catechols (shown as compound ID) in panels B and C are ranked
according to their average content levels in different lots of the herbal injection; their names
and detection information are shown in Table 1.
FIG. 2. Systemic exposure to and excretion of Danshen catechols in human subjects (A and B),
rats (C–E), and dogs (F and G) receiving i.v. DanHong injection (lot number, 13011037).
Danshen catechols (shown as compound ID) in panels A–G are ranked according to their
average content levels (Fig. 1B); their names are shown in Table 1. Red, black, and green bars
are used to show the plasma, urinary, and biliary levels of the Danshen catechols after dosing,
respectively. The symbol “×” (in red) denotes the Danshen compound that was not detected.
The human subjects received a 120 min i.v. infusion dose of the herbal injection at 40
ml/subject. The rats and the dogs received an i.v. bolus dose of the herbal injection at 4.0 and
1.2 ml/kg, respectively. Because of the sample pooling, no standard deviation is shown.
FIG. 3. Systemic exposure to and excretion of metabolites of major Danshen catechols
[tanshinol (6), protocatechuic aldehyde (1), rosmarinic acid (10), salvianolic acid A (16),
salvianolic acid D (13), lithospermic acid (22), and salvianolic acid B (26)] in human subjects
(A and B), rats (C–E), and dogs (F and G) receiving i.v. DanHong injection (lot number,
13011037). The parent Danshen catechols are ranked according to their average content levels
(Fig. 1B) and their respective metabolites are shown on the right (in a left-to-right ranking
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on February 10, 2015 as DOI: 10.1124/dmd.114.061473
at ASPE
T Journals on A
ugust 1, 2020dm
d.aspetjournals.orgD
ownloaded from
DMD # 61473
- 38 -
order of methylated metabolites, sulfates and glucuronides of methylated metabolites, sulfates
and glucuronides of parent compounds, and oxidized metabolites). Only metabolites (shown
as metabolite ID) exhibiting plasma AUC0-∞ values and/or excretory amounts, which were
10% of those of their respective parent compounds at least in one species, are shown in this
figure. The metabolite ID is used to indicate the compound as a metabolite, its parent
compound, the type of metabolism, and metabolite isomer. For instance, “M10” in M102M-S-1
denotes “metabolite of Danshen catechol 10 (rosmarinic acid)”; the subscript number and
letter “2M” denotes “dimethylation”; the subscript letter “S” denotes “sulfation”, and the last
subscript number “1” denotes “the first eluted metabolite isomer”. The subscript letter “G” for
other metabolite IDs denotes “glucuronidation”. Red/pink, black/gray, and green/light green
bars represent the plasma, urinary, and biliary levels of the parent Danshen catechols/their
metabolites, respectively. The symbol “×” (in red) denotes the Danshen compounds that was
not detected. The names of metabolites and associated detection information are shown in
Table 2 (for human metabolites) and Supplemental Tables 1 (for rat metabolites) and 2 (for
dog metabolites). The human subjects received a 120 min i.v. infusion dose of the herbal
injection at 40 ml/subject. The rats and the dogs received an i.v. bolus dose of the herbal
injection at 4 and 1.2 ml/kg, respectively. Because of the sample pooling, no standard
deviation is shown.
FIG. 4. Proposed major metabolic pathways of tanshinol (6), salvianolic acid D (13),
lithospermic acid (22), protocatechuic aldehyde (1), and rosmarinic acid (10) in human
subjects receiving i.v. DanHong injection. The metabolites of salvianolic acids B (26) and A
(16) exhibited little or no detection in human plasma and urine after dosing. The names and
detection information of metabolites are shown in Table 2; their systemic exposure levels and
excretory amounts are depicted in Fig. 3A and B. Sulfation of vanillic acid (M2M) and
tanshinol (6) mainly took place in rats and dogs after dosing DanHong injection. The
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on February 10, 2015 as DOI: 10.1124/dmd.114.061473
at ASPE
T Journals on A
ugust 1, 2020dm
d.aspetjournals.orgD
ownloaded from
DMD # 61473
- 39 -
chemical structures of M6M and M6S were inferred to be 3-O-methyltanshinol and
tanshinol-3-O-sulfate, respectively, according to the data by Tian et al. (2015). The chemical
structures of M22M and M222M were inferred to be 3'-O-methyllithospermic acid and
3',3"-O-dimethyllithospermic acid, respectively, according to the data by Wang et al. (2008).
FIG. 5. Comparative in vitro metabolic stability of Danshen catechols (including tanshinol,
protocatechuic aldehyde, protocatechuic acid, salvianolic acid B, rosmarinic acid, salvianolic
acid A, salvianolic acid D, and lithospermic acid) towards metabolism reactions mediated by
COMT, SULT, UGT, and ALDH (ALDH, for protocatechuic aldehyde only). Human, rat, and
dog liver cytosols containing COMT, SULT, and ALDH were used to induce methylation,
sulfation, and oxidation of Danshen catechols, while human, rat, and dog liver microsomes
containing UGT were used to induce glucuronidation of the compounds. Green, brown, black,
and purplish-red semi-open bars denote the data of Danshen catechols undergoing
methylation, sulfation, glucuronidation, and aldehyde dehydrogenation, respectively. Green,
brown, black, and purplish-red open bars denote the data of positive controls, i.e.,
(−)-epicatechin for COMT-mediated methylation, 7-hydroxyflavone for SULT-mediated
sulfation, chrysin for UGT-mediated glucuronidation, and isovanillin for ALDH-mediated
aldehyde dehydrogenation, respectively. Values represent the means ± standard deviations (n
= 3).
FIG. 6. Methylation of Danshen catechols (including tanshinol, protocatechuic aldehyde,
protocatechuic acid, salvianolic acid B, rosmarinic acid, salvianolic acid A, salvianolic acid D,
and lithospermic acid) mediated by COMT in SAM-fortified human (A), rat (B), and dog
liver cytosols (C) over time. Blue lines/blue open circles denote the substrate compounds.
Green lines/green open circles, green lines/green semi-open circles, and green lines/green
solid circles denote monomethylated, dimethylated, and trimethylated metabolites,
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on February 10, 2015 as DOI: 10.1124/dmd.114.061473
at ASPE
T Journals on A
ugust 1, 2020dm
d.aspetjournals.orgD
ownloaded from
DMD # 61473
- 40 -
respectively. For the methylation of protocatechuic aldehyde, isovanillin was used to inhibit
the catalytic activity of ALDH in human liver cytosol. Values represent the means ± standard
deviations (n = 3).
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on February 10, 2015 as DOI: 10.1124/dmd.114.061473
at ASPE
T Journals on A
ugust 1, 2020dm
d.aspetjournals.orgD
ownloaded from
DMD # 61473
- 41 -
TABLE 1
Detection of Danshen catechol compounds in DanHong injection.
tR, chromatographic retention time; Number in bold, product ion of base peak.
ID Compound
LC/TOF-MSE data Molecular mass (Da)
Molecular formula
tR
(min)a [M−H]–
(m/z) Fragmentation profileb
(m/z) 1 Protocatechuic aldehyde 8.38 137.0241 109.0311, 108.0233 138.0317 C7H6O3 2 Protocatechuic acid 7.11 153.0191 109.0295, 108.0221 154.0266 C7H6O4 3 Caffeic acid 11.30 179.0342 135.0451, 134.0370 180.0423 C9H8O4 4 Ferulic acid 14.12 193.0505 178.0258, 134.0370, 133.0305 194.0579 C10H10O4 5 Isoferulic acid 14.75 193.0506 178.0257, 134.0373, 133.0292 194.0579 C10H10O4 6 Tanshinol 6.63 197.0455 179.0346, 135.0454, 123.0453 198.0528 C9H10O5 7 Salvianolic acid F 11.01 313.0718 295.0621, 269.0818, 203.0376,159.0446 314.0790 C17H14O6 8 Salvianolic acid G 15.92 339.0502 311.0565, 295.0614, 267.0659 340.0583 C18H12O7 9 Prolithospermic acid 11.67 357.0606 313.0706, 203.0349, 159.0458 358.0689 C18H14O8 10 Rosmarinic acid 16.85 359.0765 197.0453, 179.0345, 161.0242 360.0845 C18H16O8 11 Salvianic acid C 12.07 377.0869 359.0774, 197.0459, 179.0352, 161.0237 378.0951 C18H18O9 12 Salvianic acid C isomer 12.52 377.0862 359.0772, 197.0448, 179.0355, 161.0244 378.0951 C18H18O9 13 Salvianolic acid D 16.32 417.0827 373.0917, 197.0447, 179.0345, 175.0393 418.0900 C20H18O10 14 Isosalvianolic acid C 19.50 491.0975 311.0563, 293.0455, 249.0556 492.1056 C26H20O10 15 Salvianolic acid C 21.27 491.0978 311.0559, 293.0455, 267.0663 492.1056 C26H20O10 16 Salvianolic acid A 18.51 493.1131 313.0716, 295.0611, 185.0246 494.1213 C26H22O10 17 Salviaflaside 15.79 521.1292 359.0773, 197.0453, 161.0241 522.1373 C24H26O13 18 Lithospermic acid isomer 13.48 537.1038 493.1134,313.0721, 295.0607 538.1111 C27H22O12 19 Lithospermic acid isomer 13.80 537.1030 493.1133, 313.0726, 295.0603, 185.0249 538.1111 C27H22O12 20 Lithospermic acid isomer 14.32 537.1039 493.1134, 313.0717, 295.0604, 185.0244 538.1111 C27H22O12 21 Salvianolic acid H/I 15.38 537.1031 339.0502, 295.0617, 185.0243 538.1111 C27H22O12 22 Lithospermic acid 16.78 537.1036 493.1141, 295.0607, 185.0241 538.1111 C27H22O12 23 Salvianolic acid J 17.97 537.1037 493.1142, 295.0609, 185.0244 538.1111 C27H22O12 24 Salvianolic acid B isomer 16.03 717.1461 519.0933, 339.0511, 321.0408 718.1534 C36H30O16 25 Salvianolic acid B isomer 16.36 717.1448 519.0932, 339.0502, 321.0407 718.1534 C36H30O16
This article has not been copyedited and form
atted. The final version m
ay differ from this version.
DM
D Fast Forw
ard. Published on February 10, 2015 as DO
I: 10.1124/dmd.114.061473
at ASPET Journals on August 1, 2020 dmd.aspetjournals.org Downloaded from
DMD # 61473
- 42 -
26 Salvianolic acid B 17.41 717.1455 519.0935, 339.0504, 321.0399 718.1534 C36H30O16 27 Salvianolic acid E 18.18 717.1454 519.0938, 339.0503, 321.0403 718.1534 C36H30O16 28 4-Methoxyl salvianolic acid B 18.38 731.1599 533.1101, 353.0676, 335.0564 732.1690 C37H32O16 T
his article has not been copyedited and formatted. T
he final version may differ from
this version.D
MD
Fast Forward. Published on February 10, 2015 as D
OI: 10.1124/dm
d.114.061473 at ASPET Journals on August 1, 2020 dmd.aspetjournals.org Downloaded from
DMD # 61473
- 43 -
TABLE 2
Detection of major metabolites of tanshinol (6), protocatechuic aldehyde (1), rosmarinic acid (10), salvianolic acid A (16), salvianolic acid D (13),
and lithospermic acid (22) in human plasma and/or urine samples collected during and after an i.v. infusion dose of DanHong injection.
tR, chromatographic retention time; Number in bold, product ion of base peak. The metabolite ID is used to indicate the compound as a metabolite, its parent compound, the
type of metabolism, and metabolite isomer. For instance, “M10” in M102M-S-1 denotes “metabolite of Danshen catechol 10 (rosmarinic acid)”; the subscript number and letter
“2M” denotes “dimethylation”; the subscript letter “S” denotes “sulfation”, and the last subscript number “1” denotes “the first eluted metabolite isomer”. The subscript letter
“G” for other metabolite IDs denotes “glucuronidation”.
ID Parent compound/metabolite
LC/TOF-MSE data Molecular mass
(Da) Molecular formula
tR (min)
[M−H]− (m/z)
Fragmentation profile (m/z)
Metabolites of tanshinol (6) 6 Tanshinol 6.61 197.0455 179.0346, 135.0454, 123.0453 198.0528 C9H10O5 M6M Methyltanshinol 9.90 211.0611 193.0507, 150.0323, 134.0371 212.0684 C10H12O5
Metabolites of protocatechuic aldehyde (1)1 Protocatechuic aldehyde 8.36 137.0240 109.0311, 108.0233 138.0317 C7H6O3 2 Protocatechuic acid 7.07 153.0194 109.0295 154.0266 C7H6O4 M2M Methylprotocatechuic acid 10.8 167.0348 123.0451 168.0422 C8H8O4 M2M-G-1 Methylprotocatechuic acid glucuronide 8.04 343.0660 167.0345, 123.0443 344.0743 C14H16O10 M2M-G-2 Methylprotocatechuic acid glucuronide 8.96 343.0671 167.0351, 123.0441 344.0743 C14H16O10 M2S-1 Protocatechuic acid sulfate 10.3 232.9767 153.0193, 109.0291 233.9838 C7H6SO7 M2S-2 Protocatechuic acid sulfate 10.7 232.9759 153.0195, 109.0295 233.9838 C7H6SO7
Metabolites of rosmarinic acid (10) 10 Rosmarinic acid 16.70 359.0775 197.0453, 179.0345, 161.0242 360.0845 C18H16O8 M10M-1 Methylrosmarinic acid 16.26 373.0918 197.0446,175.0392, 179.0346 374.1001 C19H18O8 M10M-2 Methylrosmarinic acid 18.18 373.0919 197.0452,175.0389, 135.0447 374.1001 C19H18O8 M102M Dimethylrosmarinic acid 19.47 387.1078 211.0600, 193.0492, 175.0388 388.1158 C20H20O8 M102M-S-1 Dimethylrosmarinic acid sulfate 21.33 467.0649 387.1076, 211.0605, 175.0392 468.0726 C20H20SO11 M102M-S-2 Dimethylrosmarinic acid sulfate 21.44 467.0650 387.1085, 211.0601, 175.0388 468.0726 C20H20SO11
This article has not been copyedited and form
atted. The final version m
ay differ from this version.
DM
D Fast Forw
ard. Published on February 10, 2015 as DO
I: 10.1124/dmd.114.061473
at ASPET Journals on August 1, 2020 dmd.aspetjournals.org Downloaded from
DMD # 61473
- 44 -
M102M-G-1 Dimethylrosmarinic acid glucuronide 17.17 563.1411 387.1085, 211.0606, 193.0484 564.1479 C26H28O14 M102M-G-2 Dimethylrosmarinic acid glucuronide 17.59 563.1405 387.1093, 211.0607, 193.0501 564.1479 C26H28O14
Metabolites of salvianolic acid A (16) 16 Salvianolic acid A 18.41 493.1127 313.0716, 295.0611, 185.0246 494.1208 C26H22O10 M16M-G-1 Methylsalvianolic acid A glucuronide 18.62 683.1606 507.1295,335.0576,295.0599 684.1690 C33H32O16 M16M-G-2 Methylsalvianolic acid A glucuronide 19.03 683.1611 507.1285,335.0553,295.0608 684.1690 C33H32O16 M16M-G-3 Methylsalvianolic acid A glucuronide 19.46 683.1616 507.1293,335.0557,295.0608 684.1690 C33H32O16 M162M-G-2 Dimethylsalvianolic acid A glucuronide 19.76 697.1771 521.1448, 327.0865, 309.0767 698.1847 C34H34O16
Metabolites of salvianolic acid D (13) 13 Salvianolic acid D 16.30 417.0833 373.0917, 197.0447, 175.0393 418.0900 C20H18O10 M13M Methylsalvianolic acid D 17.79 431.0981 387.1073, 211.0608, 175.0392 432.1056 C21H20O10
Metabolites of lithospermic acid (22) 22 Lithospermic acid 16.75 537.1037 493.1141, 313.0725, 295.0625 538.1111 C27H22O12 M22M Methyllithospermic acid 18.00 551.1198 507.1316, 327.0869, 309.0774 552.1268 C28H24O12 M222M Dimethyllithospermic acid 19.22 565.1342 521.1436, 327.0879, 309.0753 566.1424 C29H26O12
This article has not been copyedited and form
atted. The final version m
ay differ from this version.
DM
D Fast Forw
ard. Published on February 10, 2015 as DO
I: 10.1124/dmd.114.061473
at ASPET Journals on August 1, 2020 dmd.aspetjournals.org Downloaded from
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on February 10, 2015 as DOI: 10.1124/dmd.114.061473
at ASPE
T Journals on A
ugust 1, 2020dm
d.aspetjournals.orgD
ownloaded from
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on February 10, 2015 as DOI: 10.1124/dmd.114.061473
at ASPE
T Journals on A
ugust 1, 2020dm
d.aspetjournals.orgD
ownloaded from
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on February 10, 2015 as DOI: 10.1124/dmd.114.061473
at ASPE
T Journals on A
ugust 1, 2020dm
d.aspetjournals.orgD
ownloaded from
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on February 10, 2015 as DOI: 10.1124/dmd.114.061473
at ASPE
T Journals on A
ugust 1, 2020dm
d.aspetjournals.orgD
ownloaded from
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on February 10, 2015 as DOI: 10.1124/dmd.114.061473
at ASPE
T Journals on A
ugust 1, 2020dm
d.aspetjournals.orgD
ownloaded from
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on February 10, 2015 as DOI: 10.1124/dmd.114.061473
at ASPE
T Journals on A
ugust 1, 2020dm
d.aspetjournals.orgD
ownloaded from